Introduction {#sec1-1}
============

According to Ayurveda, body comprises of seven dhatus, which are responsible for sustenance of the being. Amongst them the first dhatu i.e. Rasa has given more importance.

Any imbalance in *Dhatu* will lead to imbalance in further *Dhatus*. Its own functioning depends on the *Agni*, which if vitiated will lead to its vitiation too. In CharakaSamhita after the description of the concept of *Agni*, *Ajirna*, *Aama*, etc., the next chapter *Pandu* has been described, which is a *Rasapradoshaja* condition.

Anemia is a ubiquitous health problem marked by thereduction of hemoglobin (Hb) concentration or the hematocrit below the range of values occurring in healthy persons,\[[@ref1]\] affects a major population. According to World Health Organization (WHO) Global Database on Anemia - "Worldwide Prevalence of Anemia 1993--2005", it affects 1.62 billion people who correspond to 24.8% of the population.\[[@ref2]\] Since anemia is the most common indicator used for iron deficiency, the terms anemia and iron deficiency anemia (IDA) are sometimes used interchangeably. Iron deficiency is ranked at the top of three global hidden hungers with about one-fifth of the world\'s population is suffering from IDA.\[[@ref3]\]

The main approach for treating anemia is iron supplementation without correcting the metabolism. However, besides the lack of iron in diet, one of the main reasons of IDA is poor absorption that needs correction at the prime level.

*Pandu* is a *Pitta* dominant *Tridoshaja* disorder with involvement of vitiation of *Rasavaha Srotas*. The symptoms of *Rasavaha* Srotas vitiation are similar to symptoms of *Kapha* vitiation. Thus, to reverse the *Samprapti* (pathogenesis) such formulation is needed which can counteract *Pitta-Kapha* and act at *Srotas* level and correct the metabolism thereby increasing iron absorption. Since *Amalaki Rasasyana* is having *Tridoshaghna*, especially *Pitta Shamaka* (pacifying *Pitta*) property, *Rasayana* (rejuvenative), *Shonitsthapana* property and also have the capability to increase the bioavailability of iron, hence, it is planned to check the role of the drug through a randomized controlled open clinical trial in the management of *Pandu* (IDA).

Materials and Methods {#sec1-2}
=====================

A total of 25 patients of IDA attending IPD/OPD of Institute for Post Graduate Teaching and Research in Ayurveda Hospital, Jamnagar, India were selected irrespective of their sex, caste, etc., taking due considerations of inclusion and exclusion criteria. The study has been approved by the Institutional Ethics Committee (PGT/7A/Ethics/2011-12/2087) and is registered to CTRI (CTRI/2013/03/003503) and consent from each patient was obtained before starting the course of treatment.

Inclusion criteria {#sec2-1}
------------------

The presence of symptoms of *Pandu* as described in classical Ayurvedic texts\[[@ref4]\] such as *Panduta* (pallor), *Daurbalya* (weakness), *Shirahshoola* (headache), *Shrama* (fatigue), and *Gaurava* (heaviness)Age between 16 and 60 yearsHb% \<12 g% (Female) and \<13 g% (male) as per WHO;\[[@ref5]\] low mean corpuscular volume (MCV) (\<80 fl); serum iron \<50 µg/dl, total iron binding capacity (TIBC) \>360 µg/dl, and transferrin saturation \<20%.

Exclusion criteria {#sec2-2}
------------------

Hemoglobin \<7 g%Patients suffering from hematological disorders such as sickle-cell anemia and thalassemia were excludedPatients suffering from severe systemic disorders such as uncontrolled hypertension, uncontrolled diabetes mellitus, AIDS, and cancerPregnant female and lactating mothers.

Laboratory investigation {#sec2-3}
------------------------

Complete blood count for hemoglobin percentage (Hb%), total red blood cell (RBC) count, hematocrit, blood indices, total leukocyte count, and differential leukocyte count. Urine for routine and microscopic, stool for routine, microscopic, and occult bloodBiochemical investigation for serum iron, total iron binding capacity (TIBC), fasting blood sugar, urea, creatinine, lipid profile, and proteins.

Grouping and posology {#sec2-4}
---------------------

Registered patients were divided into 2 groups randomly using random number table method.

Group A: *Amalaki Rasayana* groupDose - 2 g of *Amalaki Rasayana* thrice a day for 45 days*Anupana* (adjuvant) - honey and cow\'s ghee in unequal proportionGroup B: Standard control group (ferrous fumarate + folic acid)Dose - ferrous fumarate in the dosage of 150 mg/day equivalent to 50 mg of elemental iron once a day empty stomach for 45 days with water.

Method of preparation of *Amalaki Rasayana* {#sec2-5}
-------------------------------------------

Powdered *Amalaki Churna* (powder of *Phyllanthus emblica* L.) was procured from the Pharmacy, Gujarat Ayurved University, Jamnagar, while mature and fresh fruits of *Amalaki* were procured from the local market and juice was extracted out of them. The powder was triturated with fresh *Amalaki* juice in an end runner for 8 h/day for 7 days. It was then sun-dried and powdered in grinding machine.

Criteria for assessment {#sec2-6}
-----------------------

***Subjective parameters***

The effect was assessed on the basis of relief in symptoms. For the assessment, a scoring pattern was adopted which is as follows

Symptom Score

*Panduta* (Pallor)Absent 0Visible only in the sclera 1Visible only in the sclera and nail both 2Visible in the sclera, nails, face, tongue, etc. 3*Daurbalya* (general weakness)No weakness 0Slight weakness but work can be completed 1Weakness due to which work is interrupted 2Weakness affecting routine work 3*Shirahshoola* (headache)No headache 0Occasional headache 1--2 times/month; mildand relieved by rest 1Headache 3--4 times/month; relieved byrest or local application 2\>4 times/month; severe with nausea andrequire medicine 3*Shwasa* (dyspnea)Dyspnea after heavy work but relievedsoon and up to tolerance 0Dyspnea after moderate work but relievedlater and up to tolerance 1Dyspnea after little work but relieved soonand up to tolerance 2Dyspnea without any work, not relieved andbeyond to tolerance 3*Hridspandan* (palpitation)Absent 0Present only during some exercise that subsidesitself on rest 1Present during the normal routine activitiesthat subsides itself on rest 2Present during the normal routine activitiesbut does not subside on rest 3*Aruchi* (anorexia)Normal desire for food 0Desire for food, little late than normal time 1Desire for food only to favorite items 2No desire at all 3*Akshikuta Shotha* (periorbital edema)Absent 0Occasional 1Daily, periorbital edema in morning relievedin later part of day 2Persistent 3*Pindikodweshtanam* (leg cramps)Absent 0After heavy work 1Only at night but beyond tolerate 2Whole day, without work, severe, require medicine 3*Brahma* (giddiness)No giddiness 0Sometimes experience giddiness which isnot disturbing the routine work 1Often experience giddiness which needsrest and disturbs routine work 2Regular giddiness which needs treatment 3*Rukshata* (dryness) in - *Twaka*, *Nakha*, *Hastapadatala*, *Kesha*Absent 0In any 2 of these 1In any 3 of these 2In all 3*Gaurava* (heaviness)No heaviness 0Feeling of heaviness once/twice a day withoutaffecting normal routine 1Feeling of heaviness throughout the day butnot up to the extent to affect normal routine 2Feeling of heaviness throughout the daywhich hampers normal routine 3*Shrama* (fatigue)No fatigue 0Increased fatigue over baseline, but not alteringnormal activities 1Moderate/difficulty in performing some activities 2Severe, loss of ability to perform activity 3

***Objective parameters***

The following laboratory findings were assessed before and after treatment: Hemoglobin percentage (Hb%), red blood cell (RBC) count, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), serum iron, total iron binding capacity (TIBC).

Overall effect of therapy {#sec2-7}
-------------------------

The overall effect of therapy was assessed on the basis of following criteria:

Complete remission: 100%Marked improvement: \>75--\<100% improvementModerate improvement: \>50--\<75% improvementImproved: \>25--\<50% improvementUnchanged: \<25% improvement.

Statistical analysis {#sec2-8}
--------------------

In a single group, the Wilcoxon signed rank test was used to check the significance of subjective criteria and paired '*t*'-test for objective criteria was applied. To compare the effect of therapy in two groups, Chi-square test for subjective criteria and unpaired '*t*'-test for objective criteria were used. The value *P* \< 0.05 considered to be significant.

Follow-up {#sec2-9}
---------

One month follow-up was taken after treatment to check recurrences.

***Observations***

Total 25 patients were registered, 14 in Group A and 11 in Group B. One patient dropped out in each group. The 48% (*n* = 12) patients registered for the study were in between 16 and 25 years followed by 28% (*n* = 7) in 36--45 years and 20% (*n* = 5) in 26--35 years. Maximum 92% (*n* = 23) patients were females while remaining were male. 82.6% females were having regular menstruation. Menorrhagia was found in 34.78% females. Forty-eight percent (*n* = 12) patients were vegetarians. Poor appetite was found in 44% patients (*n* = 11). Habit of *Vishamasana* was found in 64% (*n* = 16) patients. *Mandagni* (diminished digestive capacity was found in 56% (*n* = 14) patients. Majority of the patients 76% (*n* = 19) were afflicted to *Lavana Rasa* (salty taste) while *Guru* (heavy), *Ushna* (hot), and *Snigdha* (unctuous) dominant diet was found in 68% (*n* = 17), 76% (*n* = 19), and 52% (*n* = 13) patients, respectively. Sixty percent (*n* = 15) and 64% (*n* = 16) patients had the habit of *Diwaswapa* (day sleeping) and *Vega Vidharana* (suppression of urges) while 68% (*n* = 19) were addicted to tea. *Chinta* (anxiety) was found in 96% (*n* = 24) and *Krodha* (anger) in 60% (*n* = 15).

On *Srtoasa* examination in *Annavaha Sroto Dushti*, *Chardi* (vomiting) was reported by 24% (*n* = 6), *Aruchi* (anorexia) by 80% (*n* = 20) patients, *Avipaka* (indigestion) by 52% (*n* = 13) patients. In the symptoms of *Rasavaha Sroto Dushti*, *Panduta* (pallor) was found in 100% (*n* = 25), *Tandra* (drowsiness) in 92% (*n* = 23) patients and *Angmarda* (body ache) in 84% (*n* = 21) patients. 68.42% patients each complained of *Glani* and *Agnimandya Tama* was reported by 63.16% while *Shabdasahishnuta* (intolerance to noise) and *Hrillas* (nausea) were reported by 68% (*n* = 17) and 48% (*n* = 12) patients, respectively. *Amla Prarthana* (desire for sour items), cardinal feature of *Raktavaha Srotodushti* was seen among 64% (*n* = 16) patients. Among the total patients, 80% (*n* = 20) complained of *Gatrasadanam* (a feature of vitiation of *Mamsavaha Srotas*). Chief complaints presented by the patients are enlisted in [Table 1](#T1){ref-type="table"}.

###### 

Cardinal symptom wise distribution of 25 patients of *Pandu* (IDA)

![](AYU-36-290-g001)

Results {#sec1-3}
=======

After completion of therapy, Group A showed highly significant relief in *Panduta* (pallor), *Daurbalya* (weakness), *Shirahshoola* (headache), *Shrama* (fatigue), and *Gaurava* (heaviness in body) while statistically significant improvement was found in *Aruchi* (anorexia) and *Pindikodweshtan* (leg cramps) \[[Table 2](#T2){ref-type="table"}\]. Standard Control showed significant relief in *Panduta* (Pallor), *Daurbalya* (weakness), *Hridspandana* (palpitation), *Pindikodweshtan* (calf muscles cramps), *Bhrama* (giddiness), *Shrama* (fatigue), and *Gaurava* (heaviness in the body) \[[Table 3](#T3){ref-type="table"}\]. On hematological values, both the groups showed insignificant increase in Hb%, RBC, and packed cell volume. On blood cell indices, *Amalaki Rasayana* showed significant increase in MCV and MCH while standard control showed insignificant increase on cell indices. On biochemical markers, the standard control group showed significant increase *n* serum iron (*P* \< 0.01) and significant decrease in TIBC (*P* \< 0.05). On transferrin saturation, both the groups showed significant increase (*P* \< 0.01) \[Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}\].

###### 

Effect of *Amalaki Rasayana* on clinical features of *Pandu* (IDA) in Group A
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###### 

Effect of therapy on clinical features of *Pandu* (IDA) in Group B
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###### 

Effect of *Amalaki Rasayana* on hematological and biochemical parameters in Group A (*n*=13)
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###### 

Effect of therapy on hematological and biochemical parameters in Group B (*n*=10)
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On comparing Group A with Group B statistically insignificant results were found indicating that both the groups are equally effective in alleviating the chief symptoms \[[Table 6](#T6){ref-type="table"}\]. On comparison, highly significant difference (*P* \< 0.001) was noted statistically on transferrin saturation while significant difference was found in S. Iron and TIBC (*P* \< 0.05). On rest other parameters insignificant results were found \[[Table 7](#T7){ref-type="table"}\]. Overall effect of therapy depicted in [Figure 1](#F1){ref-type="fig"}.

###### 

Comparative effect of therapy on clinical features in Group A and B
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###### 

Comparative effect of therapy on hematological and biochemical parameters in Group A and B

![](AYU-36-290-g007)

![Overall effect of therapy](AYU-36-290-g008){#F1}

During the follow-up the patients were kept on routine OPD treatment and insignificant changes were noticed.

Discussion {#sec1-4}
==========

The prevalence of IDA was found to be more in females. This can be due to insufficient dietary habits, social negligence, unawareness and menstrual causes. Menorrhagia, is one common cause of Iron deficiency anaemia and affects nearly 2 million women. Heavy menstrual bleeding has been reported in approximately 10-15% of all women at some point during their life. Among these women, as many as 20% develops anaemia.\[[@ref6]\] The WHO report also shows that worldwide sex incidence is more in females (41.8% pregnant and 30.2% non-pregnant females).\[[@ref7]\] A maximum number of patients were of 16--25 years of age. This is the growing period with extra needs. Furthermore, in this age group, there is more indulgence to faulty dietary habits and regime. Most of the patients in the study were vegetarian. The reason can be: (1) Vegetarian dominant area and (2) iron which is available from vegetarian sources is non-heme iron which has less bioavailability.\[[@ref8]\] The increased tannin and phytate content with vegetarian diet inhibit iron absorption.

Maximum patients were having *Mandagni*. The hampered *Agni* ultimately leads to *Agnimandya*, which leads to *Dhatvagnimandya*. These also produce *Dhatushaithilya* or *Dushti* and may also cause the vitiation of *Dosha*. Maximum patients, i.e., 63.16% were taking *Lavana Rasa* dominant diet. According to classics, excessive use of *Lavana Rasa* causes *Pitta Prakopa* (vitiation of *Pitta*).\[[@ref9]\] Majority of the patients were addicted to tea. Polyphenolic compounds present in tea also strongly inhibit dietary non-heme iron absorption.\[[@ref10]\]

*Diwaswapa* (day sleeping) was found in a maximum number of patients which vitiates all three *Doshas* as per Sushruta\[[@ref11]\] and especially *Kapha* and *Pitta* as per Acharya Charaka\[[@ref12]\] which then pin down the normal functioning of *Agni*.

Since in this study majority of the patients were female, it was quite obvious to have habit of *Vegadharana* (suppression of urges) as there is a general tendency of females to suppress their urges not only due to shyness in public gatherings, etc., but also at home too in an urge to finish the household work first. Such a habit leads to *Vata prakopa* (vitiation of *Vata*) and diminution of *Agni*. *Chinta* (anxiety) was profoundly found in patients followed by *Krodha* (anger). *Chinta* weakens the digestive power and that ultimately is responsible for vitiation of *Rasavahasrotas* resulting in *Aruchi* (anorexia), *Angamarda* (body ache), etc.\[[@ref13]\] *Krodha* is also responsible for *Jatharagni Mandya* and leads to *Aam* formation\[[@ref14]\] and is also a symptom of *Pitta Prakopa*, the main *Dosha* involved in *Pandu*.

In Group A, statistically highly significant improvement was found in pallor, weakness, headache, fatigue and heaviness in body while statistically significant improvement was found in anorexia and leg Cramps. This can be attribute to *Tridoshahara*, *Rochana*, *Dipana*, and *Anulomana* properties of *Amalaki Rasayana* which have a role in the digestion, absorption, and motility of digestive materials in the gut. Again because of having properties such as *Hridya*, *Tridoshahara*, and *Madhura Vipaka*, *Amalaki Rasayana* does nourishment of *Rasa Dhatu* which further nourishes all the *Dhatus*. It has been considered as a potent *Rasayana* enhancing the essence of all the *Dhatus*.\[[@ref15]\] *Pandu* is a disease with *Kleda Adhikya*. *Amalaki* contains 5 *Rasas* including *Tikta* (bitter) and *Kashaya* (astringent) which are *Srotoshodhaka* and *Ruksha* in property. *Tikta* and *Kashaya* are said to be *Kledopshoshana* and *Kleda Upyokta*, respectively.\[[@ref16]\] All these properties help in *Kleda Shoshana* thus alleviating the symptoms. *Amalaki* is also a potent source of Vitamin C (ascorbic acid) which is the most potent enhancer of nonheme iron absorption.\[[@ref17]\] Adding a Vitamin C source to a meal increases non-heme iron absorption up to six-fold which makes the absorption of nonheme iron as good as or better than that of heme iron.\[[@ref18]\] Further, ascorbic acid facilitates iron absorption by forming a chelate with ferric iron at acid pH that remains soluble at the alkaline pH of the duodenum.\[[@ref19]\] *Amalaki* is also having antioxidant properties by virtue of antioxidants present in it which include Vitamin C, bioflavonoids, flavones, polyphenols, and carotenoids.\[[@ref20]\] As oxidative stress, an increase in oxidants and/or a decrease in antioxidant capacity is one of the potential biochemical mechanisms involved in the pathogenesis of IDA,\[[@ref21]\] supplementation of antioxidant vitamins with iron supplementation may offer a better response in the management of IDA.\[[@ref22]\]

Standard control provided statistically significant relief in pallor, weakness, palpitations, calf muscle cramps, giddiness, fatigue and heaviness in the body. Biochemical markers increased significantly while Hb%, PCV MCV and MCH were insignificantly increased. According to WHO guidelines for iron supplementation, iron supplements are necessary for rapid treatment of IDA.\[[@ref23]\] The standard control contains elemental iron fortified with folic acid. leading to replenishment of deficient iron and correction of disease.

On Comparing the effect of therapy on symptoms, insignificant difference show that more or less both the therapies have more or less equal effect. However on objective parameters significant increase was found in S.Iron and TIBC. This may be attributed to the presence of *Iron* in *standard control*.

Conclusion {#sec1-5}
==========

Iron Deficiency Anemia can be studied under the broad umbrella of *Pandu*. *Pandu*, a *Rasaja* disorder vitiates the *Kapha* which in turn may cause the disease by *Ama* and *Mandagni*. In the present study, there was no statistical difference between ferrous fumarate + folic acid group and *Amalaki Rasayana* group but clinically ferrous fumarate + folic acid group was more effective than Amalaki *Rasayana*. On biochemical markers that is Serum Iron and ferrous fumarate + folic acid was found to be more effective than *Amalaki Rasayana* owing to iron supplementation. Replenishment of deficient iron by iron supplementation may correct the anemia but it doesn't correct the ongoing pathogenesis which is the prime aim of Ayurvedic management. A sufficient time is required to cure *Ama* and *Agnimandya* at *Dhatu* level. In this study trial drug was given for 1½ months which might not be the sufficient time to disrupt the pathogenesis. Results could have been more effective if study would have been done for longer duration considering the chronic nature of disease.
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